Notice2023-07117
Prospective Grant of an Exclusive Patent License: Manufacture, Distribution, Sale and Use of T-Cell-Based Immunotherapies for Solid Tumors
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 6, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Cancer Institute, both institutes of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to EnZeta Inc. of the State of Delaware.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 66 (Thursday, April 6, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 66 (Thursday, April 6, 2023)]
[Notices]
[Pages 20544-20545]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-07117]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Manufacture,
Distribution, Sale and Use of T-Cell-Based Immunotherapies for Solid
Tumors
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Eunice Kennedy Shriver National Institute of Child Health
and Human Development and the National Cancer Institute, both
institutes of the National Institutes of Health, Department of Health
and Human Services, are contemplating the grant of an Exclusive Patent
License to practice the inventions embodied in the Patents and Patent
Applications listed in the Supplementary Information section of this
Notice to EnZeta Inc. of the State of Delaware.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before April 21, 2023 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated Exclusive Patent License
should be directed to: Richard T. Girards, Jr., Esq., MBA, Senior
Technology Transfer Manager, National Institutes of Health, NCI
Technology Transfer Center by email (<a href="/cdn-cgi/l/email-protection#87f5eee4efe6f5e3a9e0eef5e6f5e3f4c7e9eeefa9e0e8f1"><span class="__cf_email__" data-cfemail="35475c565d5447511b525c4754475146755b5c5d1b525a43">[email protected]</span></a>) or phone
(240-276-6825).
SUPPLEMENTARY INFORMATION:
Intellectual Property
E-010-2021: Enhanced Antigen Reactivity of Immune Cells Expressing a
Mutant Non-Signaling CD3 Zeta Chain
1. United States Provisional Patent Application No. 63/113,428,
filed 13 November 2020 (HHS Reference No. E-010-2021-0-US-01);
2. International Patent Application No. PCT/US2021/059109, filed 12
November 2021 (HHS Reference No. E-010-2021-0-PCT-02); and
3. any and all other U.S. and ex-U.S. patents and patent
applications claiming priority to any one of the foregoing, now or in
the future.
The patent and patent application rights in these inventions have
been assigned and/or exclusively licensed to the government of the
United States of America.
The prospective exclusive license territory may be worldwide and
the fields of use may be limited to the following: manufacture,
distribution, sale and use of T-cell-based immunotherapies for solid
tumors.
These technologies disclose, e.g., cells expressing a modified CD3
subunit chain comprising at least one ITAM deletion. The inventive
cells and populations thereof can be formulated into a composition,
such as a pharmaceutical composition. Such cells and compositions
thereof can be utilized to treat a wide variety of conditions,
including but not limited to the indications within the scope of the
contemplated exclusive license.
This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR
404. The prospective exclusive license will be royalty bearing, and the
prospective exclusive license may be granted unless within fifteen (15)
days from the date of this published Notice, the National Cancer
Institute receives written evidence and argument that establishes that
the grant of the license would not be consistent with the requirements
of 35 U.S.C. 209 and 37 CFR 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information from these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
[[Page 20545]]
Dated: March 30, 2023.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2023-07117 Filed 4-5-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 6, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.